Literature DB >> 28284234

Humoral immune system targets clonotypic antibody-associated hepatitis C virus.

Amruta S Naik1, Brendan A Palmer1, Orla Crosbie2, Elizabeth Kenny-Walsh2, Liam J Fanning1.   

Abstract

Hypervariable region 1 (HVR1) is one of the potential neutralization domains in the E2 glycoprotein of hepatitis C virus (HCV). Point mutations of the HVR1 can lead to humoral immune escape in HCV-infected patients. In this study, we segregated the chronically infected viraemic sera from HCV-infected patients into populations of antibody-free virus and antibody-associated virus (AAV) and mapped potential epitopes within the E1E2 gene junction of AAV sequences (residues 364-430). Furthermore, we generated HCV pseudoparticles (HCVpp) derived from AAV sequences to assess their infectivity. We studied the neutralization potential of virus-free Fab obtained from antibody-virus complexes, in the HCVpp system. We observed selective targeting of clonotypic HCV variants from the quasispecies pool. Moreover, we identified potential neutralizing epitopes within the HVR1 and an additional epitope that overlapped with a broadly neutralizing AP33 epitope (amino acid 412-423 in E2). We observed a marked difference in the infectivity of HCVpp generated using E1E2 sequences isolated from AAV. We document reduction in the infectivity of HCVpp-H77 and HCVpp derived from AAV sequences when challenged with virus-free Fab. Our results provide novel insights into the complexities of engagement between HCV and the humoral immune system.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28284234     DOI: 10.1099/jgv.0.000659

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  1 in total

1.  Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.

Authors:  Amruta S Naik; Ania Owsianka; Brendan A Palmer; Ciaran J O'Halloran; Nicole Walsh; Orla Crosbie; Elizabeth Kenny-Walsh; Arvind H Patel; Liam J Fanning
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.